Jim Cramer’s top 10 things to watch in the stock market Friday

Jim Cramer’s top 10 things to watch in the stock market Friday


Republican presidential nominee, former U.S. President Donald Trump welcomes Robert F. Kennedy Jr. to the stage at a Turning Point Action campaign rally at the Gas South Arena on October 23, 2024 in Duluth, Georgia.

Anna Moneymaker | Getty Images

My top 10 things to watch Friday, Nov. 15

1. President-elect Donald Trump’s decision to nominate prominent vaccine skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services has vast implications for drug companies. That’s why shares of pharma stocks, and vaccine makers in particular, sold off late Thursday when reports of the pick first surfaced. We own Eli Lilly for the Club.

2. Warren Buffett’s Berkshire Hathaway sold most of its stake in Ulta Beauty in the third quarter after only building its position in the second quarter, regulatory filings show. Did Buffett ever know about the Ulta stake beyond the cursory? Not clear. He never spoke to management. Worth noting: Buffett has two investing lieutenants, Ted Weschler and Todd Combs, who control some money.

3. On the other hand, Berkshire built a stake in Domino’s Pizza in the quarter, sending shares of the chain higher Friday. Should you buy Domino’s off of Berkshire’s move? Maybe buy Domino’s off of CEO Russell Weiner. We don’t know how involved Buffett is anymore. Is he titular on these investments?



Source

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to  billion
Health

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to $12 billion

A startup widely known as “ChatGPT for doctors” raised a new funding round that values the company at $12 billion. OpenEvidence, based in Miami, Florida, closed a $250 million financing, led by Thrive Capital and DST, the company told CNBC. The startup first raised outside capital in February, when it reeled in $75 million from […]

Read More
Another alliance of health care and AI signals why pharma stocks should be back in favor
Health

Another alliance of health care and AI signals why pharma stocks should be back in favor

Bristol Myers Squibb and Microsoft ‘s new partnership aimed at accelerating early detection of lung cancer marks the latest way health care and artificial intelligence are rapidly intersecting. Bristol Myers said on Tuesday it will work with Microsoft’s AI-powered radiology platform to develop and launch imaging algorithms. These new tools, which can be used to […]

Read More
Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry
Health

Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry

US President Donald Trump arrives for an announcement in the Roosevelt Room of the White House in Washington, DC, US, on Friday, Dec. 19, 2025. Will Oliver | Bloomberg | Getty Images Drug pricing. Looming patent cliffs. Dealmaking. The first year of Trump 2.0. Those are among the themes that dominated conversations last week as drugmakers […]

Read More